DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Memantine in the Treatment of Kleptomania

Information source: University of Chicago
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Kleptomania

Intervention: Memantine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Chicago

Official(s) and/or principal investigator(s):
Jon E Grant, MD, JD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute


The goal of the proposed study is to evaluate the efficacy and safety of memantine in kleptomania.

Clinical Details

Official title: Memantine Treatment of Kleptomania: An Open-Label Study

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Yale Brown Obsessive Compulsive Scale Modified for KM (KM-YBOCS)

Secondary outcome:

Kleptomania Symptom Assessment Scale (K-SAS)

Clinical Global Impression Severity Scales (CGI)

Detailed description: The proposed study will consist of 8 weeks of treatment with memantine in 10 subjects with kleptomania. The hypothesis to be tested is that memantine will be effective in reducing the urges to steal in patients with kleptomania. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: 1. men and women age 18-65 2. current KM using the clinician-administered Structured Clinical Interview for Kleptomania (SCI-K) 3. stealing behavior within 2 weeks prior to enrollment. Exclusion Criteria: 1. infrequent stealing (i. e. less than one time per week) that does not meet proposed criteria for KM 2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen 3. history of seizures 4. myocardial infarction within 6 months 5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential 6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions 7. clinically significant suicidality 8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders (Grant et al., 2005), except for nicotine dependence 9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID 10. current or recent (past 3 months) DSM-IV substance abuse or dependence 11. positive urine drug screen at screening 12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline 13. previous treatment with memantine; and 14) treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

Locations and Contacts

University of Minnesota, Minneapolis, Minnesota 55454, United States
Additional Information

Starting date: March 2009
Last updated: January 17, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017